PsilocyZim

There are still many advancements to be made in psychedelic pharmacology; although, research has found that are known to be non-chemically addictive, and patients often undergo a deeply spiritual experience, leaving with a positive, open-minded outlook.

Sadly, since the enactment of the Controlled Substances Act (CSA) of 1970 and the United Nations Convention on Psychotropic Substances of 1971, psychedelics have been unjustly classified as harmful, illicit substances. These measures halted an academic pursuit to understand them or to use them to support the mounting mental health disorder rates.

Fortunately, public opinion is swaying for the decriminalization and medicinal usage of psychedelics. can help provide millions suffering from disorders with a more affordable, less addictive, therapeutic solution. What is truly unique about psychedelics is their ability to help patients introspect, enabling them to heal, rather than numb their problems. As these substances become less stigmatized, they will offer the opportunity to limit the negative patient outcomes seen from other prescription drugs.

Despite being hailed as the "psychedelic renaissance” psychedelic drug research is being held back by UK rules and attitudes, say, scientists.

Approximately 18% of people aged 18- 54 have an anxiety disorder. Anxiety disorders include panic disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder and this number is expected to increase as the population grows.

We firmly believe that enabling research will lead to the de-stigmatisation of the use of psychedelics as mental health treatments. We will proudly advocate ongoing research into the numerous mental health benefits that psilocybin can offer as an alternative solution to synthetic medicines by accelerating access to evidence-based innovative mental health treatments